| Aug 1 |
Puma Biotechnology Non-GAAP EPS of -$0.05 beats by $0.05, revenue of $47.1M beats by $2.4M
|
| Aug 1 |
Puma Biotechnology Reports Second Quarter Financial Results
|
| Jul 31 |
Puma Biotechnology Q2 2024 Earnings Preview
|
| Jul 26 |
Where Puma Biotechnology Stands With Analysts
|
| Jul 23 |
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
|
| Jul 18 |
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
|
| Jun 7 |
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
|
| Jun 3 |
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer
|
| Jun 2 |
Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)
|
| May 28 |
Puma Biotechnology to join Russell 3000 Index
|
